AstraZeneca’s DANUBE trial fails to meet primary endpoints

drug 2
The subjects of the trial included patients with transitional cell carcinoma of the urothelium, including renal pelvis, ureters, urinary bladder, and urethra. Credit: Valerie R. Yanofsky, Stephen E.Mercer, and Robert G. Phelps.